Press enter to activate the dialog and use the tab key to navigate through the options.

Alnylam Pharmaceuticals, Inc. Company Logo
  1. Top Workplaces
  2. Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals, Inc.

Alnylam has led the translation of RNAi (RNA interference) from Nobel Prize-winning discovery into an innovative, entirely new class of medicines. Founded in 2002 by a team of distinguished life sciences leaders, Alnylam’s vision is to harness the potential of RNAi therapeutics to transform the lives of people living with diseases for which there are limited or inadequate treatment options. Our pioneering work has delivered the world’s first and only approved RNAi therapeutics—ONPATTRO® (patisiran) in 2018, GIVLAARI® (givosiran) in 2019, OXLUMO® (lumasiran) in 2020, LEQVIO® (inclisiran) in 2021, and AMVUTTRA® (vutrisiran) in 2022. We are advancing a deep pipeline of innovative RNAi-based medicines in four therapeutic areas: genetic medicines, cardio-metabolic diseases, infectious diseases, and central nervous system (CNS) and ocular diseases.... Read more


Harnessing a revolution in biology for human health.... Read more


Build a top-tier, global, independent biopharmaceutical company founded on RNAi.... Read more


Commitment to People
“What we do is personal. It is about people, our greatest asset, and patients we aim to help. We genuinely care for one another and are committed to developing people, cultivating collaborative teamwork, and celebrating collective and individual accomplishments. We regularly place interests of the team before our individual needs, doing whatever it takes to help the group advance goals or meet challenges. As a Company, we also encourage product champions to fight for what they believe. We extend this spirit beyond Alnylam. Our people commit time and energy to a variety of causes enhancing our community.”

Recent Awards

  • 2022

  • 2021

  • 2020

  • 2019

Company Snapshots